bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 1 from Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer
Authors: Kandimalla Raju , Gao Feng , Matsuyama Takatoshi , Ishikawa Toshiaki , Uetake Hiroyuki , Takahashi Naoki , Yamada Yasuhide , Becerra Carlos , Kopetz Scott , Wang Xin , Goel Ajay
Published: April 2023

Supplementary Table 1: REMARK checklist.
Supplementary Table S3 from High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2
Authors: Nagano Masaaki , Kohsaka Shinji , Ueno Toshihide , Kojima Shinya , Saka Kanju , Iwase Hirotaro , Kawazu Masahito , Mano Hiroyuki
Published: April 2023

Raw data of Fig. 1C and Supplementary Fig. S2.
Supplementary Table S2 from High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2
Authors: Nagano Masaaki , Kohsaka Shinji , Ueno Toshihide , Kojima Shinya , Saka Kanju , Iwase Hirotaro , Kawazu Masahito , Mano Hiroyuki
Published: April 2023

(Table S2A) ERBB2 mutations reported in 5 different databases.(Table S2B) TCGA data analysis.(Table S2C) MSK-IMPACT data analysis.(Table S2D) ERBB2 mutation lists.(Table 2E) ERBB2 mutation lists with ERBB2 amplification.
Supplementary Data from High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2
Authors: Nagano Masaaki , Kohsaka Shinji , Ueno Toshihide , Kojima Shinya , Saka Kanju , Iwase Hirotaro , Kawazu Masahito , Mano Hiroyuki
Published: April 2023

Supplementary Figures S1-S13
Supplementary Table 1 & 2 from Chemerin Reactivates PTEN and Suppresses PD-L1 in Tumor Cells via Modulation of a Novel CMKLR1-mediated Signaling Cascade
Authors: Rennier Keith , Shin Woo Jae , Krug Ethan , Virdi Gurpal , Pachynski Russell K.
Published: April 2023

Supplementary Table 1 lists anti-human antibodies used for quantifying cell expression. Supplementary Table 2 lists Primer sequences used for RT-qPCR
Supplementary Figure 5 from Chemerin Reactivates PTEN and Suppresses PD-L1 in Tumor Cells via Modulation of a Novel CMKLR1-mediated Signaling Cascade
Authors: Rennier Keith , Shin Woo Jae , Krug Ethan , Virdi Gurpal , Pachynski Russell K.
Published: April 2023

Supplementary Figure 5. Targeted inhibitors and CMKLR1 Blocking. A. mTOR inhibitor RAD001 (everolimus; 200nM, Selleck Chemical) was used to treat DU145 tumor cells prior to chemerin exposure, and levels of indicated proteins assessed by Western blot; RAD001 suppressed expression of both pS6 and PD-L1, regardless of the presence or absence of chemerin. Taken together, these data suggest that chemerin treatment results in an increase in tumor PTEN expression, with associated changes in components of the canonical PI3K-AKT-mTOR signaling pathway as well as decreases in pS6/S6 and PD-L1 expression, comparable to PI3K and mTOR inhibitors that have been used in clinical trials. B. Flow cytometry of DU145 cells pretreated with either alpha-NETA or the blocking peptide showed >50% reduction in the binding of an anti-CMKLR1 monoclonal antibody (FAB362P, R&D Systems) compared to controls, indicating specific inhibition of CMKLR1 by these agents. Figures representative of n=2 experiments each; *p < 0.05, NS=not significant. C. A CMKLR1 blocking peptide (5uM, sc-374570 P, Santa Cruz Biotechnology) was used to treat DU145 cells in the presence or absence of chemerin. A representative western blot (left) shows a significant increase of PTEN and decrease of PD-L1 expression seen with chemerin treatment was completely abrogated in cells pretreated with the anti-CMKLR1 peptide. Western results from 3 replicates are quantified for PTEN and PD-L1 expression (right). (*p < 0.05, n = 3).
Supplementary Figure 3 from Chemerin Reactivates PTEN and Suppresses PD-L1 in Tumor Cells via Modulation of a Novel CMKLR1-mediated Signaling Cascade
Authors: Rennier Keith , Shin Woo Jae , Krug Ethan , Virdi Gurpal , Pachynski Russell K.
Published: April 2023

Supplementary Figure 3. Chemerin incubation has no significant effect on tumor cell apoptosis. DU145 tumor cells were treated with PBS or 6nM chemerin concentration for 48h. Following initial incubation, cells were continued to be treated for 24h with PBS or chemerin with or without IFN-ÃŽÂ³. An Annexin-V FITC antibody was used to stain cells going through apoptosis and 7-AAD stained each cell in the total cell population. Using three independent experiments, triplicate tubes of each cell subset were assessed via FACS (n = 3). A. Representative flow cytometry plots showing cells stained with 7-AAD only, Annexin-V FITC only, and a representative sample stained with both 7-AAD vs Annexin-V FITC. Graph of quantitative apoptosis results over 3 independent experiments. There were no significant difference in apoptosis between the PBS vs 6nM chemerin treated cells. (n = 3) B. Quantitative graph showing caspase-3/-7 expression in the control PBS vs chemerin treated cells following a 72h incubation with vehicle control (PBS) or 6nM chemerin (n = 3 independent sample sets). These results show that chemerin does not affect overall cell apoptosis or directly related caspase-3/-7 expression for 72h total incubation in all four cell lines.
Supplementary material and tables from A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer
Authors: Oza Amit M. , Estevez-Diz Maria , Grischke Eva-Maria , Hall Marcia , Marmé Frederik , Provencher Diane , Uyar Denise , Weberpals Johanne I. , Wenham Robert M. , Laing Naomi , Tracy Michael , Freshwater Tomoko , Lee Mark A. , Liu Ji , Qiu Jingjun , Rose Shelonitda , Rubin Eric H. , Moore Kathleen
Published: April 2023

Supplementary material and tables
Suppl Methods and References from AMPK Activation by Metformin Promotes Survival of Dormant ER+ Breast Cancer Cells
Authors: Hampsch Riley A. , Wells Jason D. , Traphagen Nicole A. , McCleery Charlotte F. , Fields Jennifer L. , Shee Kevin , Dillon Lloye M. , Pooler Darcy B. , Lewis Lionel D. , Demidenko Eugene , Huang Yina H. , Marotti Jonathan D. , Goen Abigail E. , Kinlaw William B. , Miller Todd W.
Published: April 2023

Supplementary methods and supplementary references cited.
Legend for Table S1 from AMPK Activation by Metformin Promotes Survival of Dormant ER+ Breast Cancer Cells
Authors: Hampsch Riley A. , Wells Jason D. , Traphagen Nicole A. , McCleery Charlotte F. , Fields Jennifer L. , Shee Kevin , Dillon Lloye M. , Pooler Darcy B. , Lewis Lionel D. , Demidenko Eugene , Huang Yina H. , Marotti Jonathan D. , Goen Abigail E. , Kinlaw William B. , Miller Todd W.
Published: April 2023

Legend for Table S1
Supplementary Table S5 from The Pharmacokinetic–Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST
Authors: Pilla Reddy Venkatesh , Anjum Rana , Grondine Michael , Smith Aaron , Bhavsar Deepa , Barry Evan , Guichard Sylvie M. , Shao Wenlin , Kettle Jason G. , Brown Crystal , Banks Erica , Jones Rhys D.O.
Published: April 2023

Tested dose and efficacy data for across tumor models investigated for AZD3229 and standard of care compounds
Supplementary Table S3 from The Pharmacokinetic–Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST
Authors: Pilla Reddy Venkatesh , Anjum Rana , Grondine Michael , Smith Aaron , Bhavsar Deepa , Barry Evan , Guichard Sylvie M. , Shao Wenlin , Kettle Jason G. , Brown Crystal , Banks Erica , Jones Rhys D.O.
Published: April 2023

GI90 for each mutation in the Ba/F3 cell viability assay panel for AZD3229, SoC agents and investigational agents
Legends for sup files from The Pharmacokinetic–Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST
Authors: Pilla Reddy Venkatesh , Anjum Rana , Grondine Michael , Smith Aaron , Bhavsar Deepa , Barry Evan , Guichard Sylvie M. , Shao Wenlin , Kettle Jason G. , Brown Crystal , Banks Erica , Jones Rhys D.O.
Published: April 2023

Legends for supplementary figures and tables
Figure S5 from Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel
Authors: Faramand Rawan , Jain Michael , Staedtke Verena , Kotani Hiroshi , Bai Renyuan , Reid Kayla , Lee Sae Bom , Spitler Kristen , Wang Xuefeng , Cao Biwei , Pinilla Javier , Lazaryan Aleksander , Khimani Farhad , Shah Bijal , Chavez Julio C. , Nishihori Taiga , Mishra Asmita , Mullinax John , Gonzalez Ricardo , Hussaini Mohammad , Dam Marian , Brandjes Brigett D. , Bachmeier Christina A. , Anasetti Claudio , Locke Frederick L. , Davila Marco L.
Published: April 2023

Noradrenaline levels in patients with grade 0, grade 1, grade 2 and grade 4 CRS respectively.
Supplementary Figure 3S - Relative mRNA expression of ABCB1 (P-gp) and ABCC1 (MRP-1) in pre- and post-treatment formalin-fixed paraffin-embedded (FFPE) tumor samples. from Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma
Authors: Alemany Regina , Moura David S. , Redondo Andres , Martinez-Trufero Javier , Calabuig Silvia , Saus Carlos , Obrador-Hevia Antonia , Ramos Rafael , Villar Victor H. , Valverde Claudia , Vaz Maria Angeles , Medina Javier , Felipe-Abrio Irene , Hindi Nadia , Taron Miguel , Martin-Broto Javier
Published: April 2023

Relative Expression shows the expression levels of ABCB1 and ABCC1 determined in FFPE samples after treatment (post-treatment) relatively to baseline levels (pre-treatment) in two cases (Relative expression = post-treatment/ pre-treatment). These results are in line with the expression of both genes determined in patient blood samples and with protein expression by immunohistochemistry. Patient 07 (leiomyosarcoma) displayed the highest radiological progression.
Figure S2 from Lineage-Specific Alterations in Gynecologic Neoplasms with Choriocarcinomatous Differentiation: Implications for Origin and Therapeutics
Authors: Xing Deyin , Zheng Gang , Pallavajjala Aparna , Schoolmeester J. Kenneth , Liu Yuehua , Haley Lisa , Hu Yan , Liu Li , Logan Lisa , Lin Yuan , Pearce Kathryn E. , Sattler Christopher A. , Tsai Ya Chea , Vang Russell , Hung Chien-Fu , Wu T.-C. , Ronnett Brigitte M.
Published: April 2023

Supplementary Figure S2
Figure S3 from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development
Authors: Palanisamy Nallasivam , Yang Jun , Shepherd Peter D.A. , Li-Ning-Tapia Elsa M. , Labanca Estefania , Manyam Ganiraju C. , Ravoori Murali K. , Kundra Vikas , Araujo John C. , Efstathiou Eleni , Pisters Louis L. , Wan Xinhai , Wang Xuemei , Vazquez Elba S. , Aparicio Ana M. , Carskadon Shannon L. , Tomlins Scott A. , Kunju Lakshmi P. , Chinnaiyan Arul M. , Broom Bradley M. , Logothetis Christopher J. , Troncoso Patricia , Navone Nora M.
Published: April 2023

Comparison of copy number changes in MDA PCa 144 PDXs
Supplementary Information from Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors
Authors: Schwartz Gregory W. , Manning Bryan , Zhou Yeqiao , Velu Priya , Bigdeli Ashkan , Astles Rachel , Lehman Anne W. , Morrissette Jennifer J.D. , Perl Alexander E. , Li Mingyao , Carroll Martin , Faryabi Robert B.
Published: April 2023

Figure S1: Characterization of FLT3-ITD clones in the FLT3i cohort. Table S1: Confusion matrix of HeatITup and genetic reviewers manual annotation for sequences in Figure 3. Table S2: Univariate Cox regression analyses for the FLT3-ITD-positive UPENN cohort. Table S3: Cox regression analysis of FLT3-ITD duplication length for the non-FLT3i-treated cohort. Table S4: Cox regression analysis of FLT3-ITD classification for the non-FLT3i-treated cohort. Table S5: Cox regression analysis of FLT3-ITD duplication length with classification for the non-FLT3i-treated cohort. Table S6: Cox regression analysis of FLT3-ITD classification for the top third longest ITD duplications in the non-FLT3i-treated cohort (Benjamini-Hochberg adjusted p-values from long non-FLT3i-treated cohort analyses). Table S7: Cox regression analysis of FLT3-ITD spacer sequence exogenous fraction for the non-FLT3i-treated cohort. Table S8: Cox regression analysis of FLT3-ITD spacer sequence exogenous fraction for the top third longest ITD duplications in the non-FLT3i-treated cohort. Table S9: Cox regression analysis of FLT3i treatment for the UPENN cohort. Table S10: Cox regression analysis of FLT3-ITD duplication length for the FLT3i-treated cohort (Benjamini-Hochberg adjusted p-values from FLT3i cohort analyses). Table S11: Cox regression analysis of FLT3-ITD classification for the FLT3i-treated cohort (Benjamini-Hochberg adjusted p-values from FLT3i cohort analyses). Table S12: Cox regression analysis of FLT3-ITD spacer sequence exogenous fraction for the FLT3i-treated cohort.
Supplementary Figure S1 from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup
Authors: Pirker Christine , Bilecz Agnes , Grusch Michael , Mohr Thomas , Heidenreich Barbara , Laszlo Viktoria , Stockhammer Paul , Lötsch-Gojo Daniela , Gojo Johannes , Gabler Lisa , Spiegl-Kreinecker Sabine , Dome Balazs , Steindl Ariane , Klikovits Thomas , Hoda Mir Alireza , Jakopovic Marko , Samarzija Miroslav , Mohorcic Katja , Kern Izidor , Kiesel Barbara , Brcic Luka , Oberndorfer Felicitas , Müllauer Leonhard , Klepetko Walter , Schmidt Wolfgang M. , Kumar Rajiv , Hegedus Balazs , Berger Walter
Published: April 2023

Supplementary Figure S1. Representative sequencing charts of the TERT promoter region harboring activating mutations.
Supplemental Material from Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative
Authors: Pishvaian Michael J. , Bender Robert J. , Halverson David , Rahib Lola , Hendifar Andrew E. , Mikhail Sameh , Chung Vincent , Picozzi Vincent J. , Sohal Davendra , Blais Edik M. , Mason Kimberly , Lyons Emily E. , Matrisian Lynn M. , Brody Jonathan R. , Madhavan Subha , Petricoin Emanuel F.
Published: April 2023

Supplementary Methods, Figures, Tables, and Legends
Supplementary file from Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer In Vitro and In Vivo
Authors: Thakur Shilpa , Daley Brianna , Gaskins Kelli , Vasko Vasyl V. , Boufraqech Myriem , Patel Dhaval , Sourbier Carole , Reece Jeff , Cheng Sheue-Yann , Kebebew Electron , Agarwal Sunita , Klubo-Gwiezdzinska Joanna
Published: April 2023

Supplementary figures and tables
APPENDIX 3 from Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer In Vitro and In Vivo
Authors: Thakur Shilpa , Daley Brianna , Gaskins Kelli , Vasko Vasyl V. , Boufraqech Myriem , Patel Dhaval , Sourbier Carole , Reece Jeff , Cheng Sheue-Yann , Kebebew Electron , Agarwal Sunita , Klubo-Gwiezdzinska Joanna
Published: April 2023

IMPACT II
Supplementary Figures Legends from KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Authors: Misale Sandra , Fatherree Jackson P. , Cortez Eliane , Li Chendi , Bilton Samantha , Timonina Daria , Myers David T. , Lee Dana , Gomez-Caraballo Maria , Greenberg Max , Nangia Varuna , Greninger Patricia , Egan Regina K. , McClanaghan Joseph , Stein Giovanna T. , Murchie Ellen , Zarrinkar Patrick P. , Janes Matthew R. , Li Lian-Sheng , Liu Yi , Hata Aaron N. , Benes Cyril H.
Published: April 2023

Legends to supplementary table, data and figures
Figure S6 from KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Authors: Misale Sandra , Fatherree Jackson P. , Cortez Eliane , Li Chendi , Bilton Samantha , Timonina Daria , Myers David T. , Lee Dana , Gomez-Caraballo Maria , Greenberg Max , Nangia Varuna , Greninger Patricia , Egan Regina K. , McClanaghan Joseph , Stein Giovanna T. , Murchie Ellen , Zarrinkar Patrick P. , Janes Matthew R. , Li Lian-Sheng , Liu Yi , Hata Aaron N. , Benes Cyril H.
Published: April 2023

Supplementary Figure 6
Figure S2 from KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Authors: Misale Sandra , Fatherree Jackson P. , Cortez Eliane , Li Chendi , Bilton Samantha , Timonina Daria , Myers David T. , Lee Dana , Gomez-Caraballo Maria , Greenberg Max , Nangia Varuna , Greninger Patricia , Egan Regina K. , McClanaghan Joseph , Stein Giovanna T. , Murchie Ellen , Zarrinkar Patrick P. , Janes Matthew R. , Li Lian-Sheng , Liu Yi , Hata Aaron N. , Benes Cyril H.
Published: April 2023

Supplementary Figure 2
Supplementary Data from Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy
Authors: Yang Linlin , Shen Changxian , Pettit Cory J. , Li Tianyun , Hu Andrew J. , Miller Eric D. , Zhang Junran , Lin Steven H. , Williams Terence M.
Published: April 2023

Esophageal/gastric cancer cells lines used in this study.
Supplemental Methods S1 from Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma
Authors: Chi Yihebali , Fang Zhiwei , Hong Xiaonan , Yao Yang , Sun Ping , Wang Guowen , Du Feng , Sun Yongkun , Wu Qiong , Qu Guofan , Wang Shusen , Song Jianmin , Yu Jianchun , Lu Yongkui , Zhu Xia , Niu Xiaohui , He Zhiyong , Wang Jinwan , Yu Hao , Cai Jianqiang
Published: April 2023

Supplemental Methods S1 contained the complete inclusion and exclusion criteria.
Supplementary Figure from Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts
Authors: Mehta Ranjit K. , Pal Sanjima , Kondapi Koushik , Sitto Merna , Dewar Cuyler , Devasia Theresa , Schipper Matthew J. , Thomas Dafydd G. , Basrur Venkatesha , Pai Manjunath P. , Morishima Yoshihiro , Osawa Yoichi , Pratt William B. , Lawrence Theodore S. , Nyati Mukesh K.
Published: April 2023

Supplementary figure 1-11
Supplemental Figure Legends from AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer
Authors: McDaniel Nellie K. , Iida Mari , Nickel Kwangok P. , Longhurst Colin A. , Fischbach Samantha R. , Rodems Tamara S. , Kranjac Carlene A. , Bo Amber Y. , Luo Qianyun , Gallagher Meghan M. , Welke Noah B. , Mitchell Kaitlyn R. , Schulz Alison E. , Eckers Jaimee C. , Hu Rong , Salgia Ravi , Hong Seungpyo , Bruce Justine Y. , Kimple Randall J. , Wheeler Deric L.
Published: April 2023

Figure legends to accompany supplemental data
Figure S6 from AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer
Authors: McDaniel Nellie K. , Iida Mari , Nickel Kwangok P. , Longhurst Colin A. , Fischbach Samantha R. , Rodems Tamara S. , Kranjac Carlene A. , Bo Amber Y. , Luo Qianyun , Gallagher Meghan M. , Welke Noah B. , Mitchell Kaitlyn R. , Schulz Alison E. , Eckers Jaimee C. , Hu Rong , Salgia Ravi , Hong Seungpyo , Bruce Justine Y. , Kimple Randall J. , Wheeler Deric L.
Published: April 2023

Synergy analysis of treatment studies using fractional product method
Figure S3 from AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer
Authors: McDaniel Nellie K. , Iida Mari , Nickel Kwangok P. , Longhurst Colin A. , Fischbach Samantha R. , Rodems Tamara S. , Kranjac Carlene A. , Bo Amber Y. , Luo Qianyun , Gallagher Meghan M. , Welke Noah B. , Mitchell Kaitlyn R. , Schulz Alison E. , Eckers Jaimee C. , Hu Rong , Salgia Ravi , Hong Seungpyo , Bruce Justine Y. , Kimple Randall J. , Wheeler Deric L.
Published: April 2023

Ctx+R428 in HN30-AXL-Y821F
Supplementary Data from Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Post Hoc Analysis of the VELOUR Trial
Authors: Van Cutsem Eric , Paccard Caroline , Chiron Marielle , Tabernero Josep
Published: April 2023

Figure legends and supplementary tables Supp Table 1. Patient demographics and baseline characteristics for the VELOUR ITT and biomarker populations. Supp Table 2. Mean plasma concentrations for the 98 biomarkers analyzed. Supp Table 3. Longitudinal analysis estimates of treatment effect by timepoint showing ANOVA p-value {less than or equal to} 0.0001 - Preprocessed data
Supplementary Table 2 from A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
Authors: Aggarwal Rahul R. , Schweizer Michael T. , Nanus David M. , Pantuck Allan J. , Heath Elisabeth I. , Campeau Eric , Attwell Sarah , Norek Karen , Snyder Margo , Bauman Lisa , Lakhotia Sanjay , Feng Felix Y. , Small Eric J. , Abida Wassim , Alumkal Joshi J.
Published: April 2023

Supplementary Table 2
Supplementary Figure 2 from A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
Authors: Aggarwal Rahul R. , Schweizer Michael T. , Nanus David M. , Pantuck Allan J. , Heath Elisabeth I. , Campeau Eric , Attwell Sarah , Norek Karen , Snyder Margo , Bauman Lisa , Lakhotia Sanjay , Feng Felix Y. , Small Eric J. , Abida Wassim , Alumkal Joshi J.
Published: April 2023

Supplementary Figure 2
Supplementary Figure 1 from Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer
Authors: Agarwal Neeraj , Nussenzveig Roberto , Hahn Andrew W. , Hoffman John M. , Morton Kathryn , Gupta Sumati , Batten Julia , Thorley Jared , Hawks Josiah , Santos Victor Sacristan , Nachaegari Gayatri , Wang Xuechen , Boucher Kenneth , Haaland Benjamin , Maughan Benjamin L.
Published: April 2023

Schematic representation of trial design, patient recruitment, arm assignment, and assignment to endpoint investigations.
Table S1 from Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers
Authors: Klein Oliver , Kee Damien , Markman Ben , Michael Michael , Underhill Craig , Carlino Matteo S. , Jackett Louise , Lum Caroline , Scott Clare , Nagrial Adnan , Behren Andreas , So Jane Y. , Palmer Jodie , Cebon Jonathan
Published: April 2023

Histological diagnoses
Table S2 from Population-based Screening for BRAFV600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis
Authors: Chu Jenny E. , Johnson Benny , Kugathasan Laveniya , Morris Van K. , Raghav Kanwal , Swanson Lucas , Lim Howard J. , Renouf Daniel J. , Gill Sharlene , Wolber Robert , Karsan Aly , Kopetz Scott , Schaeffer David F. , Loree Jonathan M.
Published: April 2023

Multivariate analysis of interaction between BRAF and MMR status in patients with metastatic colorectal cancer.
Supplemental Figure 3 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Authors: Postow Michael A. , Knox Susan J. , Goldman Debra A. , Elhanati Yuval , Mavinkurve Vikram , Wong Phillip , Halpenny Darragh , Reddy Sunil K. , Vado Kenya , McCabe Danielle , Ramirez Kristen Aufiero , Macri Mary , Schwarzenberger Paul , Ricciardi Toni , Ryan Aileen , Venhaus Ralph , Momtaz Parisa , Shoushtari Alexander N. , Callahan Margaret K. , Chapman Paul B. , Wolchok Jedd D. , Subrahmanyam Priyanka B. , Maecker Holden T. , Panageas Katherine S. , Barker Christopher A.
Published: April 2023

Levels of eotaxin were higher in cohort A compared to cohort B. Patients with response in cohort A appeared to have high levels of eotaxin. Symbols reflect unique patients.
Figure S1 from Population-based Screening for BRAFV600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis
Authors: Chu Jenny E. , Johnson Benny , Kugathasan Laveniya , Morris Van K. , Raghav Kanwal , Swanson Lucas , Lim Howard J. , Renouf Daniel J. , Gill Sharlene , Wolber Robert , Karsan Aly , Kopetz Scott , Schaeffer David F. , Loree Jonathan M.
Published: April 2023

Kaplan-Meier estimation of (A) overall survival of BRAFV600E mCRC NGS cohorts and (B) progression free survival of BRAFV600E mCRC NGS cohorts from BC Cancer and MD Anderson shows no difference in overall or progression free survival.
Supplementary Data from Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia
Authors: Danilov Alexey V. , Herbaux Charles , Walter Harriet S. , Hillmen Peter , Rule Simon A. , Kio Ebenezer A. , Karlin Lionel , Dyer Martin J.S. , Mitra Siddhartha S. , Yi Ping Cheng , Humeniuk Rita , Huang Xi , Zhou Ziqian , Bhargava Pankaj , Jürgensmeier Juliane M. , Fegan Christopher D.
Published: April 2023

Supplemental Table 1 summarizes study inclusion and exclusion criteria. Supplemental Table 2 shows the doses and dose-escalation strategy used in this study. Supplemental Table 3 defines the dose-limiting toxicities that guided dose escalation. Supplemental Table 4 lists the number of patients by disease in the dose expansion phase. Supplemental Table 5 summarizes study drug exposure. Supplemental Table 6 lists TEAEs and laboratory abnormalities of interest that occurred during the study. Supplemental Table 7 shows responders and nonresponders according to biomarker risk groups. Supplemental Table 8 shows best overall response and gene aberration status as measured by FISH and NGS. Supplemental Table 9 provides tirabrutinib peak plasma concentrations. Supplemental Table 10 summarizes tirabrutinib, idelalisib, and entospletinib plasma exposure (AUC) and maximum plasma concentrations (Cmax). Supplemental Table 11 shows patients with free BTK below the lower limit of quantitation. Supplemental Figure 1 graphically illustrates the design of the study. Supplemental Figure 2 illustrates the disposition of patients over the course of the study. Supplemental Figure 3 shows line graphs illustrating tirabrutinib plasma concentrations over time. Supplemental Figure 4 shows box plots representing BTK levels at baseline and trough tirabrutinib concentrations.
Supplemental Figure 4 from Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia
Authors: Danilov Alexey V. , Herbaux Charles , Walter Harriet S. , Hillmen Peter , Rule Simon A. , Kio Ebenezer A. , Karlin Lionel , Dyer Martin J.S. , Mitra Siddhartha S. , Yi Ping Cheng , Humeniuk Rita , Huang Xi , Zhou Ziqian , Bhargava Pankaj , Jürgensmeier Juliane M. , Fegan Christopher D.
Published: April 2023

Supplemental Figure 4. Free BTK levels at baseline and trough TIRA concentration for CLL patients treated with 80 mg TIRA
Supplemental Figure 1 from Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia
Authors: Danilov Alexey V. , Herbaux Charles , Walter Harriet S. , Hillmen Peter , Rule Simon A. , Kio Ebenezer A. , Karlin Lionel , Dyer Martin J.S. , Mitra Siddhartha S. , Yi Ping Cheng , Humeniuk Rita , Huang Xi , Zhou Ziqian , Bhargava Pankaj , Jürgensmeier Juliane M. , Fegan Christopher D.
Published: April 2023

Supplemental Figure 1. Study design
Supplementary Figure S1 from Genome Instability Profiles Predict Disease Outcome in a Cohort of 4,003 Patients with Breast Cancer
Authors: Lischka Annette , Doberstein Natalie , Freitag-Wolf Sandra , Koçak Ayla , Gemoll Timo , Heselmeyer-Haddad Kerstin , Ried Thomas , Auer Gert , Habermann Jens K.
Published: April 2023

Examples of different genome instability profiles.
Table S1 from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial
Authors: Paoletti Costanza , Barlow William E. , Cobain Erin F. , Bergqvist Mattias , Mehta Rita S. , Gralow Julie R. , Hortobagyi Gabriel N. , Albain Kathy S. , Pusztai Lajos , Sharma Priyanka , Godwin Andrew K. , Thompson Alastair M. , Hayes Daniel F. , Rae James M.
Published: April 2023

Supplementary Table 1. Patients with high sTK1 and relative median sTK1 at different time points.
Supplementary Figure 2 from Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative Neoplasms
Authors: Sharda Anish V. , Bogue Thomas , Barr Alexandra , Mendez Lourdes M. , Flaumenhaft Robert , Zwicker Jeffrey I.
Published: April 2023

Receiver operating characteristic analysis of plasma PDI levels in MPN patients who developed TE during follow up
Supplementary Table-S2 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Authors: Kandimalla Raju , Xu Jianfeng , Link Alexander , Matsuyama Takatoshi , Yamamura Kensuke , Parker M. Iqbal , Uetake Hiroyuki , Balaguer Francesc , Borazanci Erkut , Tsai Susan , Evans Douglas , Meltzer Stephen J. , Baba Hideo , Brand Randall , Von Hoff Daniel , Li Wei , Goel Ajay
Published: April 2023

Supplementary Table-S2
Supplementary Fig. 8 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Authors: Kandimalla Raju , Xu Jianfeng , Link Alexander , Matsuyama Takatoshi , Yamamura Kensuke , Parker M. Iqbal , Uetake Hiroyuki , Balaguer Francesc , Borazanci Erkut , Tsai Susan , Evans Douglas , Meltzer Stephen J. , Baba Hideo , Brand Randall , Von Hoff Daniel , Li Wei , Goel Ajay
Published: April 2023

Hierarchical clustering of EAC and healthy plasma samples
Supplementary Figure 2 from Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non–Small Cell Lung Cancer
Authors: Gavrielatou Niki , Liu Yuting , Vathiotis Ioannis , Zugazagoitia Jon , Aung Thazin Nwe , Shafi Saba , Fernandez Aileen , Schalper Kurt , Psyrri Amanda , Rimm David L.
Published: April 2023

Supplemental Figure 2. PD-L1 association with response and survival for cases that received 1stline ITx A-G and for cases that received >1st line ITx H-N.
Supplementary figure 7 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
Authors: Rijnders Maud , Balcioglu Hayri E. , Robbrecht Debbie G.J. , Oostvogels Astrid A.M. , Wijers Rebecca , Aarts Maureen J.B. , Hamberg Paul , van Leenders Geert J.L.H. , Nakauma-González J. Alberto , Voortman Jens , Westgeest Hans M. , Boormans Joost L. , de Wit Ronald , Lolkema Martijn P. , van der Veldt Astrid A.M. , Debets Reno
Published: April 2023

CD20+ B-cells are present in immune cell niches in lesions of responders upon anti-PD1 treatment
Supplementary figure 4 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
Authors: Rijnders Maud , Balcioglu Hayri E. , Robbrecht Debbie G.J. , Oostvogels Astrid A.M. , Wijers Rebecca , Aarts Maureen J.B. , Hamberg Paul , van Leenders Geert J.L.H. , Nakauma-González J. Alberto , Voortman Jens , Westgeest Hans M. , Boormans Joost L. , de Wit Ronald , Lolkema Martijn P. , van der Veldt Astrid A.M. , Debets Reno
Published: April 2023

Immune cells were mainly present in stroma areas of metastatic lesions of mUC patients.
Supplementary figure 3 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
Authors: Rijnders Maud , Balcioglu Hayri E. , Robbrecht Debbie G.J. , Oostvogels Astrid A.M. , Wijers Rebecca , Aarts Maureen J.B. , Hamberg Paul , van Leenders Geert J.L.H. , Nakauma-González J. Alberto , Voortman Jens , Westgeest Hans M. , Boormans Joost L. , de Wit Ronald , Lolkema Martijn P. , van der Veldt Astrid A.M. , Debets Reno
Published: April 2023

Clusters of peripheral blood CD4+ T-cell subsets in mUC patients with and without a tumor response to anti-PD1
Supplementary Figure from A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma
Authors: Hu Jethro L. , Omofoye Oluwaseun A. , Rudnick Jeremy D. , Kim Sungjin , Tighiouart Mourad , Phuphanich Surasak , Wang Hongqiang , Mazer Mia , Ganaway Toni , Chu Ray M. , Patil Chirag G. , Black Keith L. , Shiao Stephen L. , Wang Rongfu , Yu John S.
Published: April 2023

Supplementary Figure from A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma
Supplemental Figure 2 from Whole-body PET Imaging of T-cell Response to Glioblastoma
Authors: Nobashi Tomomi W. , Mayer Aaron T. , Xiao Zunyu , Chan Carmel T. , Chaney Aisling M. , James Michelle L. , Gambhir Sanjiv S.
Published: April 2023

Supplemental Fig. S2 Calculation of Total Lesion Immune response (TLIR). When 3D volume of interest (VOI) was placed to include a targeted lesion (green circle), Osirix MD software automatically calculates the volume above 42% of the maximum uptake within the VOI (purple area). The threshold 42% was applied following the majority of previous clinical PET studies. TLIR was defined as mean tracer uptake within the targeted VOI multiplied by volume above 42% of maximum uptake.
Supplementary Table S8 from Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer
Authors: Paracchini Lara , Beltrame Luca , Grassi Tommaso , Inglesi Alessia , Fruscio Robert , Landoni Fabio , Ippolito Davide , Delle Marchette Martina , Paderno Mariachiara , Adorni Marco , Jaconi Marta , Romualdi Chiara , D'Incalci Maurizio , Siravegna Giulia , Marchini Sergio
Published: April 2023

List of genes encoded on cytoband 19p13.11 within the significant focal regions.
Auxiliary Supplementary File from Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer
Authors: Wang Xian , Veeraraghavan Jamunarani , Liu Chia-Chia , Cao Xixi , Qin Lanfang , Kim Jin-Ah , Tan Ying , Loo Suet Kee , Hu Yiheng , Lin Ling , Lee Sanghoon , Shea Martin J. , Mitchell Tamika , Li Shunqiang , Ellis Matthew J. , Hilsenbeck Susan G. , Schiff Rachel , Wang Xiao-Song
Published: April 2023

Auxiliary Supplementary File
Supplementary Data from Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
Authors: Blum Joanne L. , Laird A. Douglas , Litton Jennifer K. , Rugo Hope S. , Ettl Johannes , Hurvitz Sara A. , Martin Miguel , Roché Henri H. , Lee Kyung-Hun , Goodwin Annabel , Chen Ying , Lanzalone Silvana , Chelliserry Jijumon , Czibere Akos , Hopkins Julia F. , Albacker Lee A. , Mina Lida A.
Published: April 2023

Supplementary Data from Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
Supplementary Methods from Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non–Small Cell Lung Cancer
Authors: Skwarski Michael , McGowan Daniel R. , Belcher Elizabeth , Di Chiara Francesco , Stavroulias Dionisios , McCole Mark , Derham Jennifer L. , Chu Kwun-Ye , Teoh Eugene , Chauhan Jagat , O’Reilly Dawn , Harris Benjamin H.L. , Macklin Philip S. , Bull Joshua A. , Green Marcus , Rodriguez-Berriguete Gonzalo , Prevo Remko , Folkes Lisa K. , Campo Leticia , Ferencz Petra , Croal Paula L. , Flight Helen , Qi Cathy , Holmes Jane , O’Connor James P.B. , Gleeson Fergus V. , McKenna W. Gillies , Harris Adrian L. , Bulte Daniel , Buffa Francesca M. , Macpherson Ruth E. , Higgins Geoff S.
Published: April 2023

Supplementary Methods
Table S7 from Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study
Authors: Delaidelli Alberto , Dunham Christopher , Santi Mariarita , Negri Gian Luca , Triscott Joanna , Zheludkova Olga , Golanov Andrey , Ryzhova Marina , Okonechnikov Konstantin , Schrimpf Daniel , Stichel Damian , Ellison David W. , von Deimling Andreas , Kool Marcel , Pfister Stefan M. , Ramaswamy Vijay , Korshunov Andrey , Taylor Michael D. , Sorensen Poul H.
Published: April 2023

Table S7
Figure S5 from TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704)
Authors: Kawazoe Akihito , Itahashi Kota , Yamamoto Noboru , Kotani Daisuke , Kuboki Yasutoshi , Taniguchi Hiroya , Harano Kenichi , Naito Yoichi , Suzuki Mitsuko , Fukutani Miki , Higuchi Tsukiko , Ikeno Takashi , Wakabayashi Masashi , Sato Akihiro , Koyama Shohei , Nishikawa Hiroyoshi , Shitara Kohei
Published: April 2023

Figure S5
Figure S4 from TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704)
Authors: Kawazoe Akihito , Itahashi Kota , Yamamoto Noboru , Kotani Daisuke , Kuboki Yasutoshi , Taniguchi Hiroya , Harano Kenichi , Naito Yoichi , Suzuki Mitsuko , Fukutani Miki , Higuchi Tsukiko , Ikeno Takashi , Wakabayashi Masashi , Sato Akihiro , Koyama Shohei , Nishikawa Hiroyoshi , Shitara Kohei
Published: April 2023

Figure S4
Figure S2 from TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704)
Authors: Kawazoe Akihito , Itahashi Kota , Yamamoto Noboru , Kotani Daisuke , Kuboki Yasutoshi , Taniguchi Hiroya , Harano Kenichi , Naito Yoichi , Suzuki Mitsuko , Fukutani Miki , Higuchi Tsukiko , Ikeno Takashi , Wakabayashi Masashi , Sato Akihiro , Koyama Shohei , Nishikawa Hiroyoshi , Shitara Kohei
Published: April 2023

Figure S2
Supplementary Table S1 from FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review
Authors: Koch Abigail L. , Vellanki Paz J. , Drezner Nicole , Li Xiaoxue , Mishra-Kalyani Pallavi S. , Shen Yuan Li , Xia Huiming , Li Yangbing , Liu Jiang , Zirkelbach Jeanne Fourie , Palazov Elitza , Gamarian Aleksandr , Choo Qiuyi , Girčys Arūnas , Rohr Ulrich-Peter , Fesenko Nataliya , Spillman Dianne , Pazdur Richard , Beaver Julia A. , Singh Harpreet
Published: April 2023

Lung Cancer Staging per AJCC 7th and 8th Editions
Table S4 from Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti–PD-1 Therapy
Authors: Telli Melinda L. , Nagata Hiroshi , Wapnir Irene , Acharya Chaitanya R. , Zablotsky Kaitlin , Fox Bernard A. , Bifulco Carlo B. , Jensen Shawn M. , Ballesteros-Merino Carmen , Le Mai Hope , Pierce Robert H. , Browning Erica , Hermiz Reneta , Svenson Lauren , Bannavong Donna , Jaffe Kim , Sell Jendy , Foerter Kellie Malloy , Canton David A. , Twitty Christopher G. , Osada Takuya , Lyerly H. Kim , Crosby Erika J.
Published: April 2023

Table S4
Supplementary Table S1 from An Allogeneic Multiple Myeloma GM-CSF–Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete Remission
Authors: Biavati Luca , Huff Carol Ann , Ferguson Anna , Sidorski Amy , Stevens M. Amanda , Rudraraju Lakshmi , Zucchinetti Cristina , Ali Syed Abbas , Imus Philip , Gocke Christian B. , Gittelman Rachel M. , Johnson Sarah , Sanders Catherine , Vignali Marissa , Gandhi Anita , Ye Xiaobu , Noonan Kimberly A. , Borrello Ivan
Published: April 2023

Supplementary Table S1
Figure S5 from Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti–PD-1 Therapy
Authors: Telli Melinda L. , Nagata Hiroshi , Wapnir Irene , Acharya Chaitanya R. , Zablotsky Kaitlin , Fox Bernard A. , Bifulco Carlo B. , Jensen Shawn M. , Ballesteros-Merino Carmen , Le Mai Hope , Pierce Robert H. , Browning Erica , Hermiz Reneta , Svenson Lauren , Bannavong Donna , Jaffe Kim , Sell Jendy , Foerter Kellie Malloy , Canton David A. , Twitty Christopher G. , Osada Takuya , Lyerly H. Kim , Crosby Erika J.
Published: April 2023

Figure S5
Supplementary Table 6 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
Authors: Even Caroline , Wang Hung-Ming , Li Shau-Hsuan , Ngan Roger K-C , Dechaphunkul Arunee , Zhang Li , Yen Chia-Jui , Chan Po Chung , Chakrabandhu Somvilai , Ma Brigette B.Y. , Tanasanvimon Suebpong , Lee Victor H.F. , Lou Pei-Jen , Li Zujun , Spira Alexander I. , Sukari Ammar , Guigay Joël , McCune Steven , Gonzalez-Maffe Juan , Szpakowski Sebastian , Yao Yao , Liang Hongzi , Mataraza Jennifer , Séchaud Romain , Manenti Luigi , Lim Darren W-T.
Published: April 2023

Supplemental Table S6. Adverse events of special interest (patients treated with spartalizumab)
Supplementary Table 3 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
Authors: Even Caroline , Wang Hung-Ming , Li Shau-Hsuan , Ngan Roger K-C , Dechaphunkul Arunee , Zhang Li , Yen Chia-Jui , Chan Po Chung , Chakrabandhu Somvilai , Ma Brigette B.Y. , Tanasanvimon Suebpong , Lee Victor H.F. , Lou Pei-Jen , Li Zujun , Spira Alexander I. , Sukari Ammar , Guigay Joël , McCune Steven , Gonzalez-Maffe Juan , Szpakowski Sebastian , Yao Yao , Liang Hongzi , Mataraza Jennifer , Séchaud Romain , Manenti Luigi , Lim Darren W-T.
Published: April 2023

Supplemental Table S3. Interval between last prior chemotherapy and first dose of study treatment
Supplementary Figure 3 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
Authors: Even Caroline , Wang Hung-Ming , Li Shau-Hsuan , Ngan Roger K-C , Dechaphunkul Arunee , Zhang Li , Yen Chia-Jui , Chan Po Chung , Chakrabandhu Somvilai , Ma Brigette B.Y. , Tanasanvimon Suebpong , Lee Victor H.F. , Lou Pei-Jen , Li Zujun , Spira Alexander I. , Sukari Ammar , Guigay Joël , McCune Steven , Gonzalez-Maffe Juan , Szpakowski Sebastian , Yao Yao , Liang Hongzi , Mataraza Jennifer , Séchaud Romain , Manenti Luigi , Lim Darren W-T.
Published: April 2023

Supplemental Figure S3. Best percentage change from baseline in sum of diameters of target lesions for patients treated with spartalizumab (A) and chemotherapy (B)
Supplementary Data from Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas
Authors: Wo Jennifer Y. , Clark Jeffrey W. , Eyler Christine E. , Mino-Kenudson Mari , Klempner Samuel J. , Allen Jill N. , Keane Florence K. , Parikh Aparna R. , Roeland Eric , Drapek Lorraine C. , Ryan David P. , Corcoran Ryan B. , Van Seventer Emily , Fetter Isobel J. , Shahzade Heather A. , Khandekar Melin J. , Lanuti Michael , Morse Christopher R. , Heist Rebecca S. , Ulysse Christine A. , Christopher Benjamin , Baglini Christian , Yeap Beow Y. , Mullen John T. , Hong Theodore S.
Published: April 2023

Supplemental Appendix 4: Molecular variants profiled by SNaPshot sequencing
Supplementary Figure 1 from PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases
Authors: Kim Guowei , Tan Hon Lyn , Sundar Raghav , Lieske Bettina , Chee Cheng Ean , Ho Jingshan , Shabbir Asim , Babak Maria V. , Ang Wee Han , Goh Boon Cher , Yong Wei Peng , Wang Lingzhi , So Jimmy B.Y.
Published: April 2023

Study timeline
Supplementary Data from PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases
Authors: Kim Guowei , Tan Hon Lyn , Sundar Raghav , Lieske Bettina , Chee Cheng Ean , Ho Jingshan , Shabbir Asim , Babak Maria V. , Ang Wee Han , Goh Boon Cher , Yong Wei Peng , Wang Lingzhi , So Jimmy B.Y.
Published: April 2023

Supplementary tables and figures
Supplementary Data from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Authors: Hussain Maha , Corcoran Claire , Sibilla Caroline , Fizazi Karim , Saad Fred , Shore Neal , Sandhu Shahneen , Mateo Joaquin , Olmos David , Mehra Niven , Kolinsky Michael P. , Roubaud Guilhem , Özgüroǧlu Mustafa , Matsubara Nobuaki , Gedye Craig , Choi Young Deuk , Padua Charles , Kohlmann Alexander , Huisden Robert , Elvin Julia A. , Kang Jinyu , Adelman Carrie A. , Allen Allison , Poehlein Christian , de Bono Johann
Published: April 2023

Supplementary Data from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Supplementary Data from Artificial Intelligence-Assisted Serial Analysis of Clinical Cancer Genomics Data Identifies Changing Treatment Recommendations and Therapeutic Targets
Authors: Fischer Catherine G. , Pallavajjala Aparna , Jiang LiQun , Anagnostou Valsamo , Tao Jessica , Adams Emily , Eshleman James R. , Gocke Christopher D. , Lin Ming-Tseh , Platz Elizabeth A. , Xian Rena R.
Published: April 2023

Supplementary Data from Artificial Intelligence-Assisted Serial Analysis of Clinical Cancer Genomics Data Identifies Changing Treatment Recommendations and Therapeutic Targets
Supplementary Figure from Cell-Free HPV DNA Provides an Accurate and Rapid Diagnosis of HPV-Associated Head and Neck Cancer
Authors: Siravegna Giulia , O'Boyle Connor J. , Varmeh Shohreh , Queenan Natalia , Michel Alexa , Stein Jarrod , Thierauf Julia , Sadow Peter M. , Faquin William C. , Perry Simon K. , Bard Adam Z. , Wang Wei , Deschler Daniel G. , Emerick Kevin S. , Varvares Mark A. , Park Jong C. , Clark John R. , Chan Annie W. , Andreu Arasa Vanessa Carlota , Sakai Osamu , Lennerz Jochen , Corcoran Ryan B. , Wirth Lori J. , Lin Derrick T. , Iafrate A. John , Richmon Jeremy D. , Faden Daniel L.
Published: April 2023

Supplementary Figure from Cell-Free HPV DNA Provides an Accurate and Rapid Diagnosis of HPV-Associated Head and Neck Cancer
Supplementary Table from Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
Authors: Lee Chung-Han , Motzer Robert , Emamekhoo Hamid , Matrana Marc , Percent Ivor , Hsieh James J. , Hussain Arif , Vaishampayan Ulka , Liu Sandy , McCune Steven , Patel Vijay , Shaheen Montaser , Bendell Johanna , Fan Alice C. , Gartrell Benjamin A. , Goodman Oscar B. , Nikolinakos Petros G. , Kalebasty Arash Rezazadeh , Zakharia Yousef , Zhang Zhentao , Parmar Hema , Akella Lalith , Orford Keith , Tannir Nizar M.
Published: April 2023

Supplementary Table from Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
Supplementary Figure from Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma
Authors: Patel Krina K. , Shah Jatin J. , Feng Lei , Lee Hans C. , Manasanch Elisabet M. , Olsem Jasper , Morphey Ashley , Huo Xiao Jiao , Thomas Sheeba K. , Bashir Qaiser , Qazilbash Muzaffar H. , Weber Donna M. , Orlowski Robert Z.
Published: April 2023

Supplementary Figure from Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma
Supplementary Figure from Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
Authors: Zhu Andrew X. , Dayyani Farshid , Yen Chia-Jui , Ren Zhenggang , Bai Yuxian , Meng Zhiqiang , Pan Hongming , Dillon Paul , Mhatre Shivani K. , Gaillard Vincent E. , Hernandez Sairy , Kelley Robin Kate , Sangro Bruno
Published: April 2023

Supplementary Figure from Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma